Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Vasomotor Symptoms of Menopause Treatment Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Vasomotor Symptoms of Menopause Treatment Market Status and Forecast (2016-2027)
      • 1.3.2 Global Vasomotor Symptoms of Menopause Treatment Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Vasomotor Symptoms of Menopause Treatment Supply by Company

    • 2.1 Global Vasomotor Symptoms of Menopause Treatment Sales Value by Company
    • 2.2 Vasomotor Symptoms of Menopause Treatment Sales Area of Main Manufacturers
    • 2.3 Trend of Concentration Rate

    3 Global and Regional Vasomotor Symptoms of Menopause Treatment Market Status by Category

    • 3.1 Vasomotor Symptoms of Menopause Treatment Category Introduction
      • 3.1.1 Estetrol
      • 3.1.2 Fezolinetant
      • 3.1.3 FP-101
      • 3.1.4 HBN-2
      • 3.1.5 Others
    • 3.2 Global Vasomotor Symptoms of Menopause Treatment Market by Category
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Vasomotor Symptoms of Menopause Treatment Market Status by End User/Segment

    • 4.1 Vasomotor Symptoms of Menopause Treatment Segment by End User/Segment
      • 4.1.1 Hospital
      • 4.1.2 Homecare
      • 4.1.3 Clinic
    • 4.2 Global Vasomotor Symptoms of Menopause Treatment Market by End User/Segment
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Vasomotor Symptoms of Menopause Treatment Market Status by Region

    • 5.1 Global Vasomotor Symptoms of Menopause Treatment Market by Region
    • 5.2 North America Vasomotor Symptoms of Menopause Treatment Market Status
    • 5.3 Europe Vasomotor Symptoms of Menopause Treatment Market Status
    • 5.4 Asia Pacific Vasomotor Symptoms of Menopause Treatment Market Status
    • 5.5 Central & South America Vasomotor Symptoms of Menopause Treatment Market Status
    • 5.6 Middle East & Africa Vasomotor Symptoms of Menopause Treatment Market Status

    6 North America Vasomotor Symptoms of Menopause Treatment Market Status

    • 6.1 North America Vasomotor Symptoms of Menopause Treatment Market by Country
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Vasomotor Symptoms of Menopause Treatment Market Status

    • 7.1 Europe Vasomotor Symptoms of Menopause Treatment Market by Country
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Vasomotor Symptoms of Menopause Treatment Market Status

    • 8.1 Asia Pacific Vasomotor Symptoms of Menopause Treatment Market by Country
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Vasomotor Symptoms of Menopause Treatment Market Status

    • 9.1 Central & South America Vasomotor Symptoms of Menopause Treatment Market by Country
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Vasomotor Symptoms of Menopause Treatment Market Status

    • 10.1 Middle East & Africa Vasomotor Symptoms of Menopause Treatment Market by Country
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Major Downstream Customers Analysis

    • 11.1 Customer One Analysis
    • 11.2 Customer Two Analysis
    • 11.3 Customer Three Analysis
    • 11.4 Customer Four Analysis

    12 Global Vasomotor Symptoms of Menopause Treatment Market Forecast by Category and by End User/Segment

    • 12.1 Global Vasomotor Symptoms of Menopause Treatment Sales Value Forecast (2022-2027)
    • 12.2 Global Vasomotor Symptoms of Menopause Treatment Forecast by Category
    • 12.3 Global Vasomotor Symptoms of Menopause Treatment Forecast by End User/Segment

    13 Global Vasomotor Symptoms of Menopause Treatment Market Forecast by Region/Country

    • 13.1 Global Vasomotor Symptoms of Menopause Treatment Market Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 TherapeuticsMD, Inc.
      • 14.1.1 Company Information
      • 14.1.2 Vasomotor Symptoms of Menopause Treatment Product Introduction
      • 14.1.3 TherapeuticsMD, Inc. Vasomotor Symptoms of Menopause Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Radius Health, Inc.
      • 14.2.1 Company Information
      • 14.2.2 Vasomotor Symptoms of Menopause Treatment Product Introduction
      • 14.2.3 Radius Health, Inc. Vasomotor Symptoms of Menopause Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Pivot Pharmaceuticals Inc
      • 14.3.1 Company Information
      • 14.3.2 Vasomotor Symptoms of Menopause Treatment Product Introduction
      • 14.3.3 Pivot Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Pherin Pharmaceuticals, Inc.
      • 14.4.1 Company Information
      • 14.4.2 Vasomotor Symptoms of Menopause Treatment Product Introduction
      • 14.4.3 Pherin Pharmaceuticals, Inc. Vasomotor Symptoms of Menopause Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Mithra Pharmaceuticals S.A.
      • 14.5.1 Company Information
      • 14.5.2 Vasomotor Symptoms of Menopause Treatment Product Introduction
      • 14.5.3 Mithra Pharmaceuticals S.A. Vasomotor Symptoms of Menopause Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 MenoGeniX, Inc.
      • 14.6.1 Company Information
      • 14.6.2 Vasomotor Symptoms of Menopause Treatment Product Introduction
      • 14.6.3 MenoGeniX, Inc. Vasomotor Symptoms of Menopause Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Euroscreen S.A.
      • 14.7.1 Company Information
      • 14.7.2 Vasomotor Symptoms of Menopause Treatment Product Introduction
      • 14.7.3 Euroscreen S.A. Vasomotor Symptoms of Menopause Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 EndoCeutics, Inc.
      • 14.8.1 Company Information
      • 14.8.2 Vasomotor Symptoms of Menopause Treatment Product Introduction
      • 14.8.3 EndoCeutics, Inc. Vasomotor Symptoms of Menopause Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Amgen Inc.
      • 14.9.1 Company Information
      • 14.9.2 Vasomotor Symptoms of Menopause Treatment Product Introduction
      • 14.9.3 Amgen Inc. Vasomotor Symptoms of Menopause Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.9.4 SWOT Analysis

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Vasomotor Symptoms of Menopause Treatment market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Vasomotor Symptoms of Menopause Treatment market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      Estetrol
      Fezolinetant
      FP-101
      HBN-2
      Others

      Segmented by End User/Segment
      Hospital
      Homecare
      Clinic

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      TherapeuticsMD, Inc.
      Radius Health, Inc.
      Pivot Pharmaceuticals Inc
      Pherin Pharmaceuticals, Inc.
      Mithra Pharmaceuticals S.A.
      MenoGeniX, Inc.
      Euroscreen S.A.
      EndoCeutics, Inc.
      Amgen Inc.
      Buy now